Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736624 | 1.00 | TAAR1 (0.60) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL681082 | 1.00 | TAAR1 (0.60) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL28389719 | 0.98 | TAAR1 (0.58) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL20746142 | 0.98 | TAAR1 (0.58) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| Ammonia Solution, Strong SCHEMBL11021206 | 0.98 | TAAR1 (0.58) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL4785594 | 0.85 | SIGMAR1 (0.64) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL24823756 | 0.82 | AGXT (0.49) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL11439744 | 0.82 | LTA4H (0.48) | MAOA | |
| SCHEMBL11380543 | 0.82 | SLC6A4 (0.69) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL11440388 | 0.82 | MAOB (0.60) | SIGMAR1SLC6A2MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200062732-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | TAAR1 4636/4885SIGMAR1 4343/4885SLC6A2 3423/4885 |
| US-20200062732-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAAR1 4636/4885SIGMAR1 4343/4885SLC6A2 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.